The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
32 | 38 | 33 | 89 |
Growth
|
63 | 73 | 51 | 3 |
Safety
|
100 | 100 | 100 | 98 |
Sentiment
|
82 | 80 | 42 | 85 |
|
77 | 77 | 74 | 91 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
73 | 80 | 73 | 65 |
Opinions Change
|
57 | 50 | 50 | 50 |
Pro Holdings
|
n/a | 60 | 38 | 97 |
Market Pulse
|
59 | 46 | 36 | 54 |
Sentiment
|
82 | 80 | 42 | 85 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
32 | 38 | 33 | 89 |
Growth
|
63 | 73 | 51 | 3 |
|
100 | 100 | 100 | 98 |
Combined
|
50 | 50 | 74 | 87 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
93 | 93 | 93 | 95 |
Price vs. Earnings (P/E)
|
9 | 5 | 5 | 17 |
Price vs. Book (P/B)
|
66 | 83 | 70 | 88 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
32 | 38 | 33 | 89 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
96 | 98 | 98 | 1 |
Profit Growth
|
32 | 17 | 4 | 56 |
Capital Growth
|
8 | 80 | 67 | 42 |
Stock Returns
|
79 | 45 | 23 | 3 |
Growth
|
63 | 73 | 51 | 3 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
100 | 100 | 100 | 70 |
Refinancing
|
85 | 79 | 77 | 71 |
Liquidity
|
95 | 95 | 95 | 100 |
|
100 | 100 | 100 | 98 |
Discover high‑ranked alternatives to AbCellera Biologics and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.